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A B S T R A C T
The final months of 2019 witnessed the emergence of a novel coronavirus in the human population. Severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) has since spread across the globe and is posing a major
burden on society. Measures taken to reduce its spread critically depend on timely and accurate identification of
virus-infected individuals by the most sensitive and specific method available, i.e. real-time reverse transcriptase
PCR (RT-PCR). Many commercial kits have recently become available, but their performance has not yet been
independently assessed.
The aim of this study was to compare basic analytical and clinical performance of selected RT-PCR kits from
seven different manufacturers (Altona Diagnostics, BGI, CerTest Biotec, KH Medical, PrimerDesign, R-Biopharm
AG, and Seegene).
We used serial dilutions of viral RNA to establish PCR efficiency and estimate the 95 % limit of detection
(LOD95). Furthermore, we ran a panel of SARS-CoV-2-positive clinical samples (n = 13) for a preliminary
evaluation of clinical sensitivity. Finally, we used clinical samples positive for non-coronavirus respiratory viral
infections (n = 6) and a panel of RNA from related human coronaviruses to evaluate assay specificity.
PCR efficiency was ≥96 % for all assays and the estimated LOD95 varied within a 6-fold range. Using clinical
samples, we observed some variations in detection rate between kits. Importantly, none of the assays showed
cross-reactivity with other respiratory (corona)viruses, except as expected for the SARS-CoV-1 E-gene.
We conclude that all RT-PCR kits assessed in this study may be used for routine diagnostics of COVID-19 in
patients by experienced molecular diagnostic laboratories.
1. Introduction
Coronavirus disease 2019 (COVID-19) is caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). This virus emerged
in the human population in the final months of 2019 from a, so far
unidentified, animal reservoir and has since spread across the globe [1].
The SARS-CoV-2 pandemic poses an enormous burden on society,
economic and healthcare systems worldwide, and various measures are
being taken to control its spread. Many of these measures critically
depend on the timely and accurate diagnosis of virus-infected in-
dividuals. Real-time reverse transcription polymerase chain reaction
(RT-PCR) is the most sensitive and specific assay and therefore pre-
ferred [2,3]. Whereas many COVID-19 RT-PCR kits are currently
commercially available, an independent assessment of these products is
not yet publicly available and direly needed to guide implementation of
accurate tests in a diagnostic market that is flooded with new tests. As
of 11 April 2020, the FIND organization listed 201 molecular assays on
their website as being on the market (www.finddx.org/covid-19/
pipeline).
Coronaviruses are positive-stranded RNA viruses that express their
replication and transcription complex, including their RNA-dependent
RNA polymerase (RdRp), from a single, large open reading frame re-
ferred to as ORF1ab [4]. The coronavirus structural proteins, including
the envelope (E), nucleocapsid (N), and spike (S) proteins, are ex-
pressed via the production of subgenomic messenger RNAs, which
during certain stages of the replication cycle far outnumber (anti)
genomic RNAs. The ORF1ab/RdRp, E, N, and S genes are the targets
most frequently used for SARS-CoV-2 detection by RT-PCR. For ex-
ample, the “Corman” PCR, which was co-developed in our lab and is
now routinely used for our in-house diagnostic work, targets a
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combination of the E-gene and the RdRp-gene [2]. In this set-up, the E-
gene primer/probe set is specific for bat(-related) betacoronaviruses,
and therefore detects both SARS-CoV-1 and -2. In addition, whereas the
RdRp-gene primers are also specific for bat(-related) betacoronaviruses,
two probes are used: one specific for bat(-related) betacoronaviruses
and another specific for SARS-CoV-2. In this study we only used the
RdRp probe that is specific for SARS-CoV-2.
Here, we provide a comparison of a selection of seven readily
available COVID-19 RT-PCR kits from different manufacturers
(Table 1). One of these kits (BGI) was recently also included in a
comparative study of various SARS-CoV-2 primer/probe sets [5]. Most
of the selected kits are CE-IVD certified and can be produced in large
quantities. Using a dilution series of SARS-CoV-2 RNA we determined
the 95 % limit of detection (LOD95) for each of these assays. In addi-
tion, a concise panel of clinical samples (n = 22) was run to provide a
first indication of clinical sensitivity and specificity. Although some kits
appeared to perform better than others at identifying clinical samples at
very low concentrations of SARS-CoV-2 RNA, all tests were able to
identify positive samples with Ct ≤ 34.5 in our in-house E-gene PCR.
Therefore, we conclude that all of the RT-PCR kits assessed in this study
may be used for routine diagnostics of COVID-19 by experienced mo-
lecular diagnostic laboratories.
2. Methods
2.1. Selection of kits
Commercially available COVID-19 RT-PCR kits were identified via
the FindDx website (www.finddx.org/covid-19/pipeline, March 2020)
and requests for information and sample kits were sent via e-mail to
approximately 20 manufacturers and/or distributors, focusing on those
kits that had already obtained CE-IVD certification. Promising com-
mercial kits were selected based on: 1) listing on the FindDx website; 2)
responsiveness to requests; 3) accessible information (in English); 4)
compatibility with different PCR platforms; 5) considerable production
capacity. Notably, all of the PCR kits that we had selected for our
analysis have in the meantime also been selected for the first round of
independent evaluation by FIND (www.finddx.org/covid-19/sarscov2-
eval-molecular/, April 2020). All of the kits included in our analysis
were provided free of charge and none of the manufacturers were in-
volved in the assessment and interpretation of the results. The selection
encompasses both kits that require transport and storage at −20 °C and
kits that can be transported and stored at room temperature. Target
genes for each RT-PCR kit were available in the assay documentation or
upon request (for an overview, see Table 1). All PCRs were run on a
LightCycler 480 II (LC480II, Roche) and performed according to the
manufacturer’s instructions for use. Of note however, for some kits
(BGI, KH Medical, and Seegene) settings for the LC480II were not
provided and were therefore adapted from those provided for another
machine.
2.2. PCR efficiency and limit of detection
To establish PCR efficiency we first ran a duplicate 10-fold dilution
series of viral RNA for each assay. Viral RNA was isolated from SARS-
CoV-2 viral particles (hCoV-19/Netherlands/Diemen_1363454/2020,
GISAID: EPI_ISL_413570) obtained from cell culture using the MagNA
Pure LC Total Nucleic Acid Isolation Kit (Roche). We determined the
slope by linear regression in GraphPad Prism and defined the required
levels for PCR efficiency (E) and R2 as> 95 % and>0.95, respectively.
Next, we ran four replicates of a 2-fold dilution series (diluted in yeast
carrier RNA in water) to determine the LOD95 by Probit analysis using
SPSS Statistics (IBM, version 24). The limited range of the dilution
series did not allow for determination of a confidence interval for the
LOD95 for all assays, which should therefore be regarded as an ap-
proximation and not considered definitive. The starting concentration
of the viral RNA (copies/mL) was determined by digital PCR targeting
the SARS-CoV-2 RdRp-gene and was specific for the positive sense
genomic RNA [2].
2.3. Clinical sensitivity and specificity
Finally, a panel of clinical samples with in-house confirmed SARS-
CoV-2 (17.25 ≤ Ct ≤ 34.0 for the E-gene during initial diagnostics; n
= 13) or other respiratory viruses (influenza virus type A (n = 2),
rhinovirus (n = 2), RSV-A and -B) was prepared (for Ct values obtained
in initial diagnostics, see Supplementary Table S1). RNA was isolated
anew from stored clinical samples (naso- and/or oropharyngeal swabs
in GLY-medium) using the MagNA Pure 96 DNA and Viral NA Small
Volume Kit (Roche) and was assessed with a single replicate to obtain a
first indication of clinical specificity and sensitivity. No re-test was
performed when the result was inconclusive according to the manu-
facturer’s instructions for interpretation of the result (n = 2). In addi-
tion to clinical samples, a panel of viral RNA from related cell cultured
Table 1
Overview of kits for RT-PCR-based detection of SARS-COV-2 included in the study.
Manufacturer Country Catalog number Storage condition Regulatory status Target gene(s)
Altona Diagnostics Germany 821003 −20 °C RUOb Ea, S
BGI China MFG030010 −20 °C CE-IVD ORF1ab
CerTest Biotec Spain VS-NCO213L RT CE-IVD ORF1ab, N
KH Medical Korea RV008 −20 °C CE-IVD RdRp, S
PrimerDesign England Z-Path-COVID-19-CE −20 °Cc CE-IVD RdRp
R-Biopharm AG Germany PG6815RUO −20 °C RUOd E
Seegene Korea RP10244Y −20 °C CE-IVD RdRp, N, Ea
Abbreviations: CE-IVD, European conformity label-in vitro diagnostics; E, envelope protein of SARS-CoV-2; RdRp, RNA-225 dependent RNA polymerase of SARS-
CoV-2; N, nucleocapsid protein of SARS-CoV-2; ORF1ab, open reading frame 1a and b 226 of SARS-CoV-2, includes the RdRp; RNA-dependent RNA polymerase of
SARS-CoV-2, part of ORF1ab; RT, room 227 temperature; RT-PCR, reverse-transcription polymerase chain reaction; RUO, research use only; S, spike protein of SARS-
228 CoV-2; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
a As does the in-house “Corman” E-gene PCR, these E-gene assays are specific for bat(-related) betacoronaviruses, i.e. they detect both SARS-CoV-1 and -2.
b According to manufacturer’s website the kit is RUO, the FindDx website states CE-IVD certification for this kit.
c Shipment is performed at RT.
d According to the manufacturer, CE-IVD certification will be applied for in the near future.
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human coronaviruses (including SARS1, MERS, NL63, OC43, and 229E)
was used to assess cross-reactivity within the coronavirus family (for Ct
values of these samples see Supplementary Table S1).
3. Results
3.1. PCR efficiency was above the required level for all kits included in the
study
We first assessed PCR efficiency for each target gene assay by run-
ning a duplicate 10-fold dilution series of SARS-CoV-2 viral RNA
(Fig. 1). All assays showed an efficiency ≥96 % and R squares
were< 0.97, which are both well above the pre-defined required level.
Since the applied filter settings were not correct for reading the Seegene
N-gene assay, we excluded these data from all of our analyses.
3.2. The LOD95 varied within a 6-fold range between the kits included in
the study
The 10-fold dilution series provided a first indication of the LOD95
for each assay and were used to determine the starting point of a 2-fold
dilution series performed with four replicates to come to a more precise
estimate (for Ct values, see Supplementary Table S2). Probit analysis
was performed to estimate the LOD95, which is shown in Table 2.
Notably, due to the limited extent of the dilution series, this analysis did
not always provide upper and lower bounds of the estimate and should
not be considered definitive. We found that the estimated LOD95 for
the various targets of the RT-PCR kits varied within a 6-fold range, with
the RT-PCR kit from Altona Diagnostics having the lowest LOD95 at 3.8
copies/mL for both the E- and S-gene assays and the PrimerDesign kit
having the highest LOD95 at 23 copies/mL (Table 2). Overall, our in-
house “Corman” RT-PCR had the lowest estimated LOD95 at 0.91 co-
pies/mL for the E-gene assay [2].
Fig. 1. PCR efficiency for seven commercially available RT-PCR kits for the detection of SARS-CoV-2 RNA. PCR efficiency (E) for each target gene was assessed
using a duplicate 10-fold dilution series of SARS-CoV-2 viral RNA. Linear regression was performed in Graphpad Prism to obtain the slope and R2. The percentage
efficiency was calculated from the slope using the formula E = 100*(-1 + 10−1/slope). E-gene, gene encoding the envelope protein of SARS-CoV-2; RdRp, RNA-
dependent RNA polymerase of SARS-CoV-2; N, nucleocapsid protein of SARS-CoV-2; ORF1ab, open reading frame 1a and b of SARS-CoV-2, includes the RdRp; RNA-
dependent RNA polymerase of SARS-CoV-2, part of ORF1ab; RT-PCR, reverse-transcriptase polymerase chain reaction; S, spike protein of SARS-CoV-2; SARS-CoV-2,
severe acute respiratory syndrome coronavirus 2.
Table 2
Estimated limit of detection for SARS-COV-2 in copies/mL for individual assays.
LOD95 in copy/mL determined in this studya
Company E N ORF1ab/RdRp S
Altona Diagnostics 3.8 (NA) – – 3.8 (NA)
BGI – – 4.3 (NA) –
CerTest Biotec – 4.8 (NA) 18 (13−56) –
KH Medical – – 4.8 (NA) 4.3 (NA)
PrimerDesign – – 23 (16−123) –
R-Biopharm AG 4.3 (NA) – – –
SeeGene 4.8 (NA) NAb 18 (13−56) –
In-house PCR 0.91 (0.61−2.4) – 3.1 (2.1−7.3) –
Abbreviations: E, envelope protein of SARS-CoV-2; LOD95, 95 % limit of de-
tection; N, nucleocapsid protein of SARS-CoV-2; NA, not available; ORF, open
reading frame; RdRp, RNA-dependent RNA polymerase of SARS-CoV-2; RT-
PCR, reverse-transcription polymerase chain reaction; S, spike protein of SARS-
CoV-2; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
a The copy number was determined by digital PCR for the positive sense
RdRp gene. Due to the limited range of the 2-fold dilution series, a confidence
interval could not be determined for all assays.
b The filter settings for the Seegene N-gene PCR were not correct and these
results are therefore excluded.
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3.3. The clinical sensitivity appears to vary between the kits included in the
study
Next, we analyzed a panel of clinical samples previously submitted
for routine SARS-CoV-2 diagnostics (n = 13) for which the presence of
various amounts of SARS-CoV-2 RNA had been confirmed using our in-
house PCR. In addition, we included a panel of clinical samples (n = 6)
with other confirmed respiratory viral infections, including influenza
virus type A, RSV A and B, and rhinovirus. Notably, the new RNA
isolation performed on stored clinical samples resulted in increased Ct
values (by approximately 1 Ct) compared to the initial diagnostic re-
sults for our in-house E-gene PCR. The positive identification rate for
the various RT-PCR kits varied from 10 to 13 out of 13 samples
(Fig. 2A), with R-Biopharm AG performing best (13/13), followed by
BGI, KH Medical, and Seegene (12/13), CerTest BioTec (11/13), and
Altona Diagnostics and PrimerDesign (10/13). Of note, Seegene had
one “inconclusive” sample according to the manufacturer’s instructions
for interpretation, which might have tested positive upon re-testing but
has now been counted as “negative”. All target gene assays were able to
positively identify the 10 clinical samples with the highest
concentrations of SARS-CoV-2 (Ct ≤ 34.50 in our in-house E-gene
PCR). For these samples, the different assays showed a similar pattern
of Ct values, on average ranging from almost 1 Ct lower (Altona Di-
agnostics S-gene) to almost 5 Ct higher (KH Medical S-gene) than those
obtained with the in-house E-gene PCR (Fig. 2B).
3.4. None of the assays showed cross-reactivity with circulating respiratory
(corona)viruses
Importantly, none of the assays resulted in a positive signal for any
of the clinical samples with confirmed non-coronavirus respiratory viral
infections (Supplementary Table S1). We also ran a panel consisting of
cell culture-derived viral RNA for related human coronaviruses (SARS1,
MERS, NL63, OC43, and 229E) to check for cross-reactivity within the
coronavirus family. Of these, only the SARS-CoV-1 E-gene was identi-
fied, as per design, by assays from Altona Diagnostics, Seegene, and our
in-house PCR (Supplementary Table S1).
Fig. 2. Different RT-PCR kits showed
variations in detection rate and Ct
values. RNA isolated from stored
SARS-CoV-2-positive clinical samples
using the MagNA Pure 96 DNA and
Viral NA Small Volume Kit (Roche) was
subjected to the various RT-PCR assays
according to the manufacturer’s in-
structions for use, on a LightCycler 480
II (Roche). A) Graph depicts Ct values
obtained for all clinical samples (n =
13) in all RT-PCR assays. Data points
above the horizontal dotted line are
negative, for plotting purposes in-
dicated with Ct 42.5. The detection rate
of the complete RT-PCR kit is indicated
below the data points, e.g. 10/13
means 10 out of 13 samples tested po-
sitive according to the instructions for
data interpretation provided by the
manufacturer. For the Seegene kit, one
sample was “inconclusive” according to
the manufacturer’s guide for inter-
pretation and was therefore counted as
“negative”, although a signal was ob-
served for at least one target. B) Graph
depicts only data for those clinical
samples (n = 10) with the highest
concentration of SARS-CoV-2 RNA and
which were positively identified by all
RT-PCR assays. The lines show the
mean Ct value for each assay, triangles
show the Ct values of the samples with
the highest (sample 1) and lowest
(sample 10) concentration according to
the in-house E-gene PCR. E, envelope
protein of SARS-CoV-2; RdRp, RNA-
dependent RNA polymerase of SARS-
CoV-2; N, nucleocapsid protein of
SARS-CoV-2; ORF1ab, open reading
frame 1a and b of SARS-CoV-2, in-
cludes the RdRp; RNA-dependent RNA
polymerase of SARS-CoV-2, part of
ORF1ab; RT-PCR, reverse-transcriptase
polymerase chain reaction; S, spike
protein of SARS-CoV-2; SARS-CoV-2,
severe acute respiratory syndrome
coronavirus 2.
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4. Discussion
Here we provide a comparison of seven commercially available RT-
PCR kits for the detection of SARS-CoV-2 in clinical samples. All RT-
PCR kits performed satisfactorily regarding PCR efficiency (≥96 %)
and the estimated LOD95 varied within a 6-fold range between kits
(3.8–23 copies/mL). Notably, the copy number concentration of the
standard was determined by digital PCR on the positive sense RdRp
gene and therefore provides an indication of the number of viral par-
ticles per ml. The actual copy number for each RT-PCR target and ac-
companying limit of detection may vary depending on, for example, the
amount of subgenomic messenger RNA-containing cells that are present
in the (clinical) sample.
From a selection of clinical samples with various concentrations of
viral RNA (n = 13), all RT-PCR kits were able to positively identify the
ten samples with the highest concentrations of SARS-CoV-2 RNA (Ct ≤
34.5 in our in-house E-gene PCR). To provide an indication on clinical
relevance of this finding: from our in-house diagnostic data on patients
presenting with COVID-19 symptoms, it appears that from all in-
dividuals testing positive for our in-house E-gene PCR (n = 416) the
proportion of individuals with a Ct value>34.5 is approximately 3.6 %
(unpublished data). The R-Biopharm AG kit positively identified the
highest number of clinical samples, i.e. 13 out of 13, comparable with
our in-house PCR. Three kits were able to positively identify 12 out of
13 samples (BGI, KH Medical, Seegene). Notably, we performed our
analysis using only a small number of clinical samples and we therefore
advise that diagnostic laboratories in the field conduct additional and
more extensive in-house clinical validations upon implementation of
novel RT-PCR kits. Importantly, none of the assays showed cross-re-
activity towards a panel of other respiratory (corona)viruses, except for
the expected cross-reactivity with the SARS-CoV-1 E-gene. Since the
latter virus is no longer known to be circulating in the human popu-
lation, we consider this cross-reactivity acceptable.
Considering our findings, we believe that all of the commercially
available RT-PCR kits included in this study can be used for routine
diagnostics of symptomatic COVID-19 patients. When performing virus
diagnostics in populations that may be expected to display low viral
loads, such as health-care workers with mild or no symptoms or pa-
tients during later stages of the infection [6], it might be advisable to
use those kits that performed best regarding the positive identification
of clinical samples, i.e. RT-PCR kits from R-Biopharm AG, BGI, KH
Medical, and Seegene.
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